External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application

Objective We previously derived and validated a risk score for major nonsteroidal anti‐inflammatory drug (NSAID) toxicity over 1 year among NSAID users in a randomized controlled trial. This work was extended to examine the risk score's performance in an external population using real‐world dat...

Full description

Bibliographic Details
Main Authors: Daniel H. Solomon, Nina P. Paynter, Hongshu Guan, Joel M. Kremer
Format: Article
Language:English
Published: Wiley 2020-05-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11134
id doaj-99c1084c8bef4337b377413b3e95fea1
record_format Article
spelling doaj-99c1084c8bef4337b377413b3e95fea12020-11-25T02:03:45ZengWileyACR Open Rheumatology2578-57452020-05-012526927510.1002/acr2.11134External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World ApplicationDaniel H. Solomon0Nina P. Paynter1Hongshu Guan2Joel M. Kremer3Brigham and Women's Hospital Boston MassachusettsBrigham and Women's Hospital Boston MassachusettsBrigham and Women's Hospital Boston MassachusettsCorrona Research FoundationObjective We previously derived and validated a risk score for major nonsteroidal anti‐inflammatory drug (NSAID) toxicity over 1 year among NSAID users in a randomized controlled trial. This work was extended to examine the risk score's performance in an external population using real‐world data. Methods Patients enrolled in the Corrona Rheumatoid Arthritis (RA) Registry were included if they initiated use of an NSAID. We defined the original risk factors previously identified in the risk score for major NSAID toxicity: age; male sex; history of cardiovascular disease, hypertension, and diabetes; tobacco use; statin use; elevated serum creatinine and hematocrit values; and RA. Additionally, we defined the occurrence of major toxicity, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality. The original risk factors were assessed in Cox regression examining discrimination and calibration. Low (less than 1%), intermediate (1%‐4%), and high (more than 4%) risk categories for 1‐year risk were applied to the population. Results A total of 5231 patients from Corrona who had a new NSAID exposure period were included. The original risk score model showed good discrimination (C‐index 0.70). Not all of the original variables were statistically significant in real‐world data. Using the original risk score weights, 1363 (26.1%) patients had predicted risk of less than 1%, 3571 (68.3%) had predicted risk of 1% to 4%, and 297 (5.7%) had predicted risk of more than 4%. Conclusion The original NSAID major toxicity risk score demonstrated good model fit characteristics in this external real‐world cohort. These results suggest that such a risk score is valid in typical practice and could be considered for clinical care.https://doi.org/10.1002/acr2.11134
collection DOAJ
language English
format Article
sources DOAJ
author Daniel H. Solomon
Nina P. Paynter
Hongshu Guan
Joel M. Kremer
spellingShingle Daniel H. Solomon
Nina P. Paynter
Hongshu Guan
Joel M. Kremer
External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application
ACR Open Rheumatology
author_facet Daniel H. Solomon
Nina P. Paynter
Hongshu Guan
Joel M. Kremer
author_sort Daniel H. Solomon
title External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application
title_short External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application
title_full External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application
title_fullStr External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application
title_full_unstemmed External Validation of a Risk Score for Major Toxicity Among Nonsteroidal Anti‐Inflammatory Drug Users: Real‐World Application
title_sort external validation of a risk score for major toxicity among nonsteroidal anti‐inflammatory drug users: real‐world application
publisher Wiley
series ACR Open Rheumatology
issn 2578-5745
publishDate 2020-05-01
description Objective We previously derived and validated a risk score for major nonsteroidal anti‐inflammatory drug (NSAID) toxicity over 1 year among NSAID users in a randomized controlled trial. This work was extended to examine the risk score's performance in an external population using real‐world data. Methods Patients enrolled in the Corrona Rheumatoid Arthritis (RA) Registry were included if they initiated use of an NSAID. We defined the original risk factors previously identified in the risk score for major NSAID toxicity: age; male sex; history of cardiovascular disease, hypertension, and diabetes; tobacco use; statin use; elevated serum creatinine and hematocrit values; and RA. Additionally, we defined the occurrence of major toxicity, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality. The original risk factors were assessed in Cox regression examining discrimination and calibration. Low (less than 1%), intermediate (1%‐4%), and high (more than 4%) risk categories for 1‐year risk were applied to the population. Results A total of 5231 patients from Corrona who had a new NSAID exposure period were included. The original risk score model showed good discrimination (C‐index 0.70). Not all of the original variables were statistically significant in real‐world data. Using the original risk score weights, 1363 (26.1%) patients had predicted risk of less than 1%, 3571 (68.3%) had predicted risk of 1% to 4%, and 297 (5.7%) had predicted risk of more than 4%. Conclusion The original NSAID major toxicity risk score demonstrated good model fit characteristics in this external real‐world cohort. These results suggest that such a risk score is valid in typical practice and could be considered for clinical care.
url https://doi.org/10.1002/acr2.11134
work_keys_str_mv AT danielhsolomon externalvalidationofariskscoreformajortoxicityamongnonsteroidalantiinflammatorydrugusersrealworldapplication
AT ninappaynter externalvalidationofariskscoreformajortoxicityamongnonsteroidalantiinflammatorydrugusersrealworldapplication
AT hongshuguan externalvalidationofariskscoreformajortoxicityamongnonsteroidalantiinflammatorydrugusersrealworldapplication
AT joelmkremer externalvalidationofariskscoreformajortoxicityamongnonsteroidalantiinflammatorydrugusersrealworldapplication
_version_ 1724946100683538432